Copay Assistance for Expensive Drugs

Evidence Driven Drug Pricing Project
October 10, 2016

Dr. Bach, along with lead author Dr. Peter Ubel of Duke-Margolis Center for Health Policy, published a piece in Annals of Internal Medicine arguing that drug company copay and coupon programs actually play a significant role in keeping prescription drug costs in the U.S. high. Many drug manufacturers point to these programs to help patients afford drugs but Bach and Ubel outline why the programs mask underlying costs and what policymakers can do to fix it.

Read the full article here.